Ann Beliën

Ann Beliën is the CEO and founder of Rejuvenate Biomed. Prior to Rejuvenate Biomed, they worked for The Janssen Pharmaceutical Companies of Johnson & Johnson from May 2007 to September 2017, where they were responsible for campus strategy and open innovation. Before that, they worked for Johnson & Johnson from April 2000 to May 2007 as a clinical and cross-ft coordinator in late development, with a focus on oncology.

Ann Beliën's educational career would involve completing a post-doctoral fellowship in neuro-oncology at ETH Zürich, followed by a PhD in neuro-oncology at the University of Zurich. Ann would then complete a masters degree in biomedical research sciences at the Vrije Universiteit Brussel.

Some direct reports include Karen Smeets - Portfolio Manager, Lizzy-Anne Neven - CFO, and Silke Hüttner - CMO.